Bubs Australia (BUB) Status update summary
Event summary combining transcript, slides, and related documents.
Status update summary
8 Apr, 2026Strategic direction and leadership
Introduced a highly experienced executive team focused on disciplined execution, global expansion, and risk management.
Emphasized robust governance, a strategic reset, and a unified operating cadence, resulting in doubled revenue and inaugural profits.
Outlined a sequenced execution plan targeting value creation, brand equity, and financial strength.
Board and leadership are deeply engaged in capital allocation discipline and performance culture.
Proven platform with high barriers to entry, strong margins, and diversified markets.
Market positioning and growth strategy
Focused on premium infant nutrition, leveraging Australian heritage, clean label credentials, and gentle digestion.
Leading in goat formula, with expansion into toddler, adult nutrition, and supplements.
Proven ability to scale in Australia, China, and the U.S., with targeted consumer engagement and digital strategies.
Targeting digitally savvy, higher-income urban parents for brand advocacy and repeat purchase.
Purpose centers on clean, gentle nutrition and lifelong wellbeing, with a mission to be trusted globally.
Financial performance and guidance
FY26 revenue guidance upgraded to AUD 120–125 million (USD $120–125M), reflecting 22–27% growth over prior year.
Underlying EBIT/EBITDA guidance for FY26 is AUD 9–11 million, with 1H FY26 EBITDA at $4.4M.
Achieved 26% revenue CAGR from FY23 to FY26, with strong operating leverage and low debt.
Capital-light business model and disciplined investment drive positive cash flow and margin growth.
Expecting to be operating cash flow positive by FY27, with disciplined working capital management.
Latest events from Bubs Australia
- Revenue up 33–34% to AUD 80m, with strong US/China growth and FY25 EBITDA breakeven targeted.BUB
H2 202412 Jun 2026 - First-ever half-year net profit and 23% revenue growth, led by US and China, with risks ahead.BUB
H1 202512 Jun 2026 - Revenue up 29% to $102.5M, first after-tax profit, and strong US-led growth.BUB
H2 202512 Jun 2026 - US-driven 14% revenue growth, 48% US surge, strong margin, but cash and regulatory risks persist.BUB
H1 202612 Jun 2026 - FY26 revenue expected at $105–115 million, with US expansion and strong liquidity supporting growth.BUB
Trading update28 May 2026 - Strong growth, margin gains, and US/China expansion set up for FY25 profitability.BUB
AGM 202413 Jan 2026 - Strong FY25 growth, global expansion, and strategic focus on FDA and China drive outlook.BUB
AGM 202520 Nov 2025 - Net revenue up 30% to $25.6m, EBITDA positive, and $22.9m in liquidity at quarter end.BUB
Q1 2026 TU30 Oct 2025 - FY25 saw 29% revenue growth, positive EBITDA, and strong US and China market performance.BUB
Q4 2025 TU28 Jul 2025